Novartis books $1.9 billion impairment, lifts full-year guidance
Novartis recorded a $1.9 billion partial impairment charge in the third quarter tied to del-desiran, the myotonic dystrophy candidate it acquired thro
Avidity
Every Fin-node story mentioning Avidity — 1 story, newest first.
Avidity · 1 story